Shares of Athersys, Inc. (NASDAQ:ATHX) saw unusually-strong trading volume on Tuesday . Approximately 2,444,277 shares traded hands during mid-day trading, an increase of 288% from the previous session’s volume of 630,438 shares.The stock last traded at $1.84 and had previously closed at $1.84.
Several analysts have commented on ATHX shares. ValuEngine lowered shares of Athersys from a “hold” rating to a “sell” rating in a research report on Tuesday, December 5th. Maxim Group set a $6.00 price objective on shares of Athersys and gave the stock a “buy” rating in a research report on Tuesday, February 13th.
The firm has a market cap of $227.39, a PE ratio of -7.08 and a beta of -0.57.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. raised its position in shares of Athersys by 9.4% in the second quarter. Vanguard Group Inc. now owns 4,265,772 shares of the biopharmaceutical company’s stock valued at $6,441,000 after purchasing an additional 366,572 shares during the period. State Street Corp raised its position in shares of Athersys by 27.2% in the second quarter. State Street Corp now owns 1,432,695 shares of the biopharmaceutical company’s stock valued at $2,161,000 after purchasing an additional 305,944 shares during the period. Northern Trust Corp raised its position in shares of Athersys by 30.8% in the second quarter. Northern Trust Corp now owns 1,123,870 shares of the biopharmaceutical company’s stock valued at $1,697,000 after purchasing an additional 264,549 shares during the period. Mckinley Capital Management LLC Delaware bought a new stake in shares of Athersys in the third quarter valued at approximately $1,093,000. Finally, Perkins Capital Management Inc. raised its position in shares of Athersys by 17.7% in the fourth quarter. Perkins Capital Management Inc. now owns 363,375 shares of the biopharmaceutical company’s stock valued at $658,000 after purchasing an additional 54,650 shares during the period. 19.66% of the stock is currently owned by institutional investors.
Athersys, Inc is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company’s MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients.
Receive News & Ratings for Athersys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys and related companies with MarketBeat.com's FREE daily email newsletter.